Home > Cardiology > More severe coronary artery calcifications with VKA than NOAC

More severe coronary artery calcifications with VKA than NOAC

ESC 2019
Treatment with vitamin K antagonists (VKA) is associated with more severe coronary artery calcifications in patients –even when adjusted for cardiovascular risk factors– than those who received new oral anticoagulants (NOAC). Additional studies are required to clarify the clinical importance of this association in terms of hard cardiovascular endpoints. Although the use of NOACs has risen considerably over the last years, VKAs are still the most frequently prescribed oral anticoagulants worldwide. They work by inhibiting vitamin K1, which is necessary to produce coagulation factors. However, VKA also inhibit vitamin K2, which plays an essential role in activating the matrix Gla protein, which acts as a strong local inhibitor of arterial calcifications. Dr Selma Hasific (Odense University, Denmark) and colleagues aimed to investigate whether treatment with VKA is associated with coronary artery calcification in individuals who had no prior cardiovascular di...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on